Securities Class Actions Target Ultragenyx Pharmaceutical After Setrusumab Phase III Fails Primary Fracture Endpoint
- Ultragenyx faces securities class actions alleging it misled investors about setrusumab Phase III Orbit and Cosmic study results.
- Ultragenyx publicly acknowledges both Phase III trials missed primary endpoints for reducing annualized clinical fracture rate.
- Ultragenyx says it will further analyze data and engage regulators; faces legal, reputational scrutiny over surrogate‑vs‑clinical outcome communication.
Legal Scrutiny of Ultragenyx’s Setrusumab Phase III Results
Rosen Law Firm and The Gross Law Firm are mounting separate securities class actions against Ultragenyx Pharmaceutical on behalf of purchasers of its common stock, alleging the company and certain executives make materially false and misleading statements about the Phase III Orbit and Cosmic studies of setrusumab (UX 143) in osteogenesis imperfecta (OI). The complaints cover purchases from Aug. 3, 2023 through Dec. 26, 2025 and allege defendants promote confidence that the antibody will reduce patients’ annualized fracture rates while downplaying or concealing adverse data about the trials’ ability to demonstrate that effect.
Central to the allegations is a scientific dispute over clinical benefit: plaintiffs contend Ultragenyx emphasizes increases in bone density from setrusumab but fails to disclose that those gains do not translate into statistically significant reductions in fracture rates. Ultragenyx is publicly acknowledging that both Phase III trials do not achieve their primary endpoints for reduction in annualized clinical fracture rate, a shortfall the company attributes to trial factors including a low fracture rate in the Orbit placebo arm and a trend in Cosmic that falls short of significance.
The lawsuits underscore intensified legal and regulatory scrutiny that follows late-stage trial disappointments in rare-disease drug development. Plaintiffs assert that management’s public statements and study design representations misled investors about the likelihood of demonstrating clinical benefit; Ultragenyx faces potential reputational and operational consequences as the litigation proceeds. Observers say the proceedings may prompt closer examination of how biopharma companies communicate surrogate outcomes, such as bone density, versus patient-centered endpoints like fractures.
Law Firms Pursue Lead Plaintiffs and Registration
Both firms invite affected shareholders to seek lead plaintiff status by an April 6, 2026 deadline and offer contingency-fee representation with no upfront costs; Rosen Law and The Gross Law Firm provide online registration portals and free portfolio monitoring for registrants. Notices emphasize strict court deadlines and procedural requirements for joining the actions and selecting lead plaintiffs.
Clinical and Industry Context
Ultragenyx, a developer of therapies for rare genetic diseases, is confronting the practical challenge of translating biomarker improvements into meaningful clinical outcomes for OI patients. The company is indicating it will analyze trial data further and engage with regulators and investigators to determine next steps, while the industry watches how this outcome shapes trial design expectations and corporate disclosure practices.
